DCC-2618C-Kit/PDGFR inhibtor CAS# 1225278-16-9 |
2D Structure
- Imatinib Mesylate (STI571)
Catalog No.:BCC1115
CAS No.:220127-57-1
- Sunitinib malate
Catalog No.:BCC3664
CAS No.:341031-54-7
- Pazopanib (GW-786034)
Catalog No.:BCC1286
CAS No.:444731-52-6
- Nintedanib (BIBF 1120)
Catalog No.:BCC3661
CAS No.:656247-17-5
- Regorafenib
Catalog No.:BCC3646
CAS No.:755037-03-7
- Amuvatinib (MP-470, HPK 56)
Catalog No.:BCC2258
CAS No.:850879-09-3
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
Cas No. | 1225278-16-9 | SDF | Download SDF |
PubChem ID | 46208890 | Appearance | Powder |
Formula | C26H21F2N5O3 | M.Wt | 489.47 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : ≥ 100 mg/mL (204.30 mM) *"≥" means soluble, but saturation unknown. | ||
Chemical Name | 1-N'-[2,5-difluoro-4-[2-(1-methylpyrazol-4-yl)pyridin-4-yl]oxyphenyl]-1-N-phenylcyclopropane-1,1-dicarboxamide | ||
SMILES | CN1C=C(C=N1)C2=NC=CC(=C2)OC3=C(C=C(C(=C3)F)NC(=O)C4(CC4)C(=O)NC5=CC=CC=C5)F | ||
Standard InChIKey | WWOXKWLDMLMYQY-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C26H21F2N5O3/c1-33-15-16(14-30-33)21-11-18(7-10-29-21)36-23-13-19(27)22(12-20(23)28)32-25(35)26(8-9-26)24(34)31-17-5-3-2-4-6-17/h2-7,10-15H,8-9H2,1H3,(H,31,34)(H,32,35) | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | DCC-2618 is a small-molecule inhibitor of KIT kinases with IC50 values of 6 nM, 9 nM, 18 nM, 5 nM, 14 nM and 9 nM for wt c-KIT, KIT V654A, KIT T670I, KIT D816H, KIT D816V and KIT JMD ΔVV/D816V respectively. | |||||
Targets | wt c-KIT | KIT V654A | KIT T670I | KIT D816H | KIT D816V | KIT JMD ΔVV/D816V |
IC50 | 6 nM | 9 nM | 18 nM | 5 nM | 14 nM | 9 nM |
DCC-2618 Dilution Calculator
DCC-2618 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.043 mL | 10.2151 mL | 20.4303 mL | 40.8605 mL | 51.0757 mL |
5 mM | 0.4086 mL | 2.043 mL | 4.0861 mL | 8.1721 mL | 10.2151 mL |
10 mM | 0.2043 mL | 1.0215 mL | 2.043 mL | 4.0861 mL | 5.1076 mL |
50 mM | 0.0409 mL | 0.2043 mL | 0.4086 mL | 0.8172 mL | 1.0215 mL |
100 mM | 0.0204 mL | 0.1022 mL | 0.2043 mL | 0.4086 mL | 0.5108 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
IC50: 6 nM, 9 nM, 18 nM, 5 nM, 14 nM and 9 nM for wt c-KIT, KIT V654A, KIT T670I, KIT D816H, KIT D816V and KIT JMD ΔVV/D816V, respectively.
DCC-2618 is a small-molecule inhibitor of KIT kinases.
Gastrointestinal stromal tumors (GIST) are driven by gain-of-function mutations of the KIT (approx 90%) or PDGFR (approx 10%) receptor tyrosine kinases. DCC-2618 has been designed to effectively inhibit the imatinib and sunitinib-sensitive KIT juxtamenbrane domin mutants as well as secondary resistant KIT iniase-domain mutants.
In vitro: DCC-2618 is a kinase switch inhibitor that can control drug resistant mutants of KIT and PDGFR in GIST. DCC-2618 acts by imposing an inactive conformation (shape) of highly resistant and aggressive secondary mutations of KIT kinase [1].
In vivo: DCC-2618 inhibits KIT in GIST tumor xenografts after single dose. At the doses of 50 and 25 mpk, DCC-2618 showed promising potency on pKIT (Y703) with the inhibition ranging from 39% to 79% 2-12 hrs after the administration [1].
Clinical trial: A Phase I trial with refractory GIST patients is planned.
Reference:
[1] DCC-2618, a small molecule inhibitor of normal and mutant KIT kinasefor treatment of refractory gastrointestinal stromal tumors (GIST)Deciphera Pharmaceuticals, Lawrence, KS.
- AG 99
Catalog No.:BCC6667
CAS No.:122520-85-8
- Naltriben mesylate
Catalog No.:BCC5683
CAS No.:122517-78-6
- Gentiside B
Catalog No.:BCN7301
CAS No.:1225022-67-2
- INK 128 (MLN0128)
Catalog No.:BCC3880
CAS No.:1224844-38-5
- GBLD 345
Catalog No.:BCC6787
CAS No.:122479-08-7
- 4-O-(3-nitropropanoyl)corollin
Catalog No.:BCC8716
CAS No.:122475-42-7
- MFZ 10-7
Catalog No.:BCC6180
CAS No.:1224431-15-5
- Paederosidic acid methyl ester
Catalog No.:BCN3439
CAS No.:122413-01-8
- Amylin
Catalog No.:BCC6017
CAS No.:122384-88-7
- Rosiglitazone
Catalog No.:BCC2264
CAS No.:122320-73-4
- 6''-O-acetylisovitexin
Catalog No.:BCN6114
CAS No.:1223097-20-8
- Vermisporin
Catalog No.:BCN1863
CAS No.:122301-98-8
- Gelomulide A
Catalog No.:BCN6580
CAS No.:122537-59-1
- Gelomulide B
Catalog No.:BCN6588
CAS No.:122537-60-4
- SKLB1002
Catalog No.:BCC4312
CAS No.:1225451-84-2
- Esculentoside T
Catalog No.:BCC1077
CAS No.:
- Ajugamarin G1
Catalog No.:BCN3659
CAS No.:122587-83-1
- Ajugamarin F4
Catalog No.:BCN3656
CAS No.:122587-84-2
- 11-Hydroxyrankinidine
Catalog No.:BCN4814
CAS No.:122590-03-8
- 11-Hydroxyhumantenine
Catalog No.:BCN4863
CAS No.:122590-04-9
- Garbanzol
Catalog No.:BCN6811
CAS No.:1226-22-8
- p-Anisil
Catalog No.:BCC9112
CAS No.:1226-42-2
- Thiazovivin
Catalog No.:BCC2525
CAS No.:1226056-71-8
- PKC fragment (530-558)
Catalog No.:BCC5830
CAS No.:122613-29-0
BLU-285, DCC-2618 Show Activity against GIST.[Pubmed:28077435]
Cancer Discov. 2017 Feb;7(2):121-122.
Tyrosine kinase inhibitors may initially control gastrointestinal stromal tumors, but most patients eventually experience disease progression due to activation loop mutations, which are resistant to approved drugs. However, phase I trials suggest that the cancer is sensitive to two new agents: BLU-285 and DCC-2618. In addition, liquid biopsies, which were used to follow patients during the trials, may be valuable tools in tracking disease progression and assessing tumor heterogeneity.